Key Takeaways:
Aardvark Therapeutics faces a securities fraud class action over its February 2025 IPO, with a lead plaintiff deadline of Oct. 13, 2026.
"We're investigating the suit's allegations, including that Aardvark allegedly misled investors about ARD-101's development, its safety and efficacy," Reed Kathrein, the Hagens Berman partner leading the firm's investigation, said.
The complaint alleges the IPO offering documents failed to disclose that ARD-101, a small-molecule therapy targeting bitter taste receptors for hyperphagia in Prader-Willi Syndrome, was less safe than represented. Unexpected reversible cardiac observations, including QRS prolongation, occurred during trials at above-target doses, the suit claims. Aardvark voluntarily paused its Phase 3 HERO trial on Feb. 27, 2026, sending shares down more than 56 percent, and the FDA placed a full clinical hold on the drug's investigational new drug application on May 14, 2026, pushing the stock down another 32.1 percent.
Investors who bought AARD common stock traceable to the Feb. 13, 2025 IPO or during the class period through May 14, 2026, must move the court by Oct. 13, 2026, to serve as lead plaintiff. Rosen Law Firm and Law Offices of Howard G. Smith have filed similar notices on behalf of affected shareholders, with the class action already filed in court.
The clinical hold halted all ongoing studies under the IND, including the HERO trial and the open-label extension, leaving the company's lead program in limbo. The lawsuit adds legal exposure on top of the regulatory setback, with potential settlements or judgments that could weigh on the clinical-stage biopharmaceutical company's balance sheet.
The Oct. 13, 2026 lead plaintiff deadline will determine who directs the litigation and could shape any potential settlement. Investors will also watch for any FDA response to Aardvark's efforts to resolve the clinical hold on ARD-101.
This article is for informational purposes only and does not constitute investment advice.
